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Abstract
Background: Antithrombin (AT) is a slow-acting progres-
sive inhibitor of activated clotting factors, particularly 
thrombin and activated factor X (FXa). However, the pres-
ence of heparin or heparan sulfate accelerates its effect 
by several magnitudes. AT deficiency, a severe throm-
bophilia, is classified as type I (quantitative) and type II 
(qualitative) deficiency. In the latter case mutations may 
influence the reactive site, the heparin binding-site (HBS) 
and exert pleiotropic effect. Heterozygous type II-HBS 
deficiency is a less severe thrombophilia than other het-
erozygous subtypes. However, as opposed to other sub-
types, it also exists in homozygous form which represents 
a very high risk of venous thromboembolism.
Methods: A modified anti-FXa chromogenic AT assay was 
developed which determines both the progressive (p) and 
the heparin cofactor (hc) activities, in parallel. The method 
was evaluated and reference intervals were established. 
The usefulness of the assay in detecting type II-HBS AT 
deficiency was tested on 78 AT deficient patients includ-
ing 51 type II-HBS heterozygotes and 18 homozygotes.
Results: Both p-anti-FXa and hc-anti-FXa assays showed 
excellent reproducibility and were not influenced by high 
concentrations of triglyceride, bilirubin and hemoglobin. 
Reference intervals for p-anti-FXa and hc-anti-FXa AT 
activities were 84%–117% and 81%–117%, respectively. 
Type II-HBS deficient patients demonstrated low (hete-
rozygotes) or very low (homozygotes) hc-anti-FXa activity 
with normal or slightly decreased p-anti-FXa activity. The 
p/hc ratio clearly distinguished wild type controls, type 
II-HBS heterozygotes and homozygotes.
Conclusions: Concomitant determination of p-anti-FXa 
and hc-anti-FXa activities provides a reliable, clinically 
important diagnosis of type II-HBS AT deficiency and dis-
tinguishes between homozygotes and heterozygotes.
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Introduction
Antithrombin (AT), a key regulator of the coagulation 
system, belongs to the family of serine protease inhibitors 
(serpins) [1–4]. AT shares the common structural/func-
tional feature of serpins; it contains three β-sheets, nine 
α-helices and a flexible reactive center loop (RCL) with 
the reactive site, exposed on top of the molecule. The term 
antithrombin is misleading, in addition to thrombin it also 
inhibits activated factor X (FXa) and, to a lesser extent, 
other active serine protease clotting factors, FIXa, FXIa, 
FXIIa [2, 5] and FVIIa complexed with tissue factor [6–8]. 
AT has two isoforms that differ only in the extent of glyco-
sylation [2, 5]. The α isoform, predominant in the circu-
lation, is N-glycosylated on Asn residues 95, 135, 155 and 
192, while the β isoform lacks glycosylation on Asn135.
AT is a suicide inhibitor, the target protease cleaves 
the scissile Arg393-Ser394 bond in RCL, and then it 
remains covalently linked to the serpin. It is a so-called 
progressive inhibitor, the rate of its reaction with throm-
bin or FXa is slow. However, the high affinity binding of 
AT to negatively charged glycosaminoglycans with spe-
cific pentasaccharide units (heparin, or heparan sulfate) 
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results in a 500- to 1000-fold acceleration of the rate of 
inhibition. The heparin-binding site (HBS) is located in 
the N-terminal part of the molecule and involves amino 
acid residues Arg47, Lys114, Lys125, Arg129 [9]. In the 
absence of heparin P14-P15 residues of RCL are inserted 
into β-sheet A, which constrains the RCL and makes it 
minimally available for interaction with its targets. The 
binding of pentasaccharide or heparin containing penta-
saccharide units to the N-terminal part of the molecule 
induces the expulsion of RCL from its entrapped position. 
The mechanism by which heparin accelerates the inhibi-
tion of thrombin and FXa is different. The allosteric effect 
of a single pentasaccharide unit is sufficient to transform 
AT into a high binding state required for the effective 
formation of Michaelis complex between AT and FXa. 
The mechanism of heparin-induced effective Michaelis 
complex formation between thrombin and AT is some-
what different. In this case the conformation change 
induced by the allosteric effect of pentasaccharide is not 
sufficient, and might not even be required. Thrombin 
also binds to heparin and the bridging effect of heparin 
containing at least 18 saccharide units is essential for its 
effective interaction with AT [10–12].
AT is a highly important thromboprotective molecule; 
the lack of AT is incompatible with life. The prevalence 
of its deficiencies in the general population is between 
1 in 2000 and 1 in 5000 [13, 14], whereas the frequency 
of AT deficiencies among patients with venous thrombo-
embolism (VTE) is between 1 in 20 and 1 in 200 [15, 16]. 
AT deficiency is classified as type I (quantitative) and 
type II (qualitative) [17]. In type I deficiency AT activ-
ity and the antigen concentration are equally decreased 
due to defective synthesis or secretion of the protein. 
Type II deficiency is usually caused by missense muta-
tion involving the reactive site (RS), the HBS, or exert-
ing a pleiotropic effect (PE) [18]. The clinical phenotype 
of type II-HBS AT deficiency differs from that of other 
subtypes. As opposed to other subtypes, its homozygous 
form is not lethal, although it results in severe VTE at an 
early age. Heterozygous type II-HBS AT deficiency is a less 
severe phenotype than other heterozygous subtypes. This 
subtype often shows incomplete penetrance or might 
even demonstrate autosomal recessive pattern. The fre-
quency of type II-HBS AT deficiency seems to show con-
siderable variation among countries/regions. The single 
publication on the occurrence of type II-HBS deficiency 
in the general population claimed a frequency of 1 in 
2500 to 1 in 3200 for this defect [19], but no supporting 
data have been provided. In Hungary this subtype seems 
to be the most prevalent AT defect; among symptomatic 
AT-deficient patients diagnosed in our laboratory during 
the last 4  years (n = 110), 81% proved to be type II-HBS 
deficient.
A scheme on the stepwise diagnosis and classifica-
tion of AT deficiency has been recommended [3]. The 
first step in the diagnostic algorithm is a chromogenic 
screening test measuring the inhibition of thrombin or 
FXa in the presence of heparin. A recent survey (2013/4) of 
ECAT Foundation showed that approximately 58% of the 
laboratories used heparin cofactor (hc) AT assay based on 
thrombin (FIIa) inhibition while 42% of them used anti-
FXa assay. We have reported that the hc-anti-FXa (hc-anti-
FXa) assay is superior over the anti-FIIa assay in detecting 
type II-HBS AT deficiency [20]. However, this screening 
test in itself does not ensure the diagnosis. It was assumed 
that the progressive anti-FXa (p-anti-FXa) activity, meas-
ured in the absence of heparin, is insensitive to HBS defect 
and its parallel measurement with hc-anti-FXa activity 
provides a tool for the diagnosis of type II-HBS deficiency. 
In this study we modified the anti-FXa chromogenic AT 
assay to measure both the hc-anti-FXa and p-anti-FXa 
activity, evaluated the assays, established their reference 
intervals and on a relatively high number of AT deficient 
patients demonstrated its usefulness in the diagnosis of 
type II-HBS deficiency.
Materials and methods
Subjects
Seventy-eight consecutively diagnosed patients with AT deficiency, 
confirmed by fluorescent DNA sequencing, were recruited for the 
study. Among the recruited patients, eight had type I defect, one 
had type II-PE, and 69 patients had type II-HBS deficiency. The latter 
group represented 51 families. Among type II-HBS deficient patients 
18 carried the mutation in homozygous form, while 51 patients were 
heterozygotes. Anti-FXa determinations were also performed on 
the plasma samples from 24 first-degree relatives of the patients, in 
which causative AT mutation was excluded by DNA sequencing. The 
reference sample group consisted of 188 apparently healthy individu-
als, 104 females and 84 males, median age: 34 [interquartile range 
(IQR): 26–41]. Exclusion criteria for the healthy group were the his-
tory of arterial and venous thrombosis and, in the case of women, 
being on oral contraceptive or pregnancy.
Ethics
The work was carried out according to the principles laid down in the 
Declaration of Helsinki and amended in 2008 by the World Medical 
Assembly in Seoul, Korea. The study protocol was approved by the 
National Ethics Committee and informed consent was obtained from 
all participants.
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Determination of heparin cofactor and progres-
sive anti-FXa activity and antithrombin antigen
The following assay protocol for the p-anti-FXa assay was adapted 
to Siemens BCS coagulometer (Marburg, Germany) and to  Ceveron 
coagulometer (Technoclone, Vienna, Austria). Ten microliter 
plasma was diluted five-fold by the addition of 40 μL 50  mmol/L 
pH 8.4 Tris-HCl buffer containing 175 mmol/L NaCl, 7.5 mol/L EDTA 
and 10 mg/L polybrene. The diluted plasma was incubated with 
50 μL 12 nkat/mL FXa for 300 s at 37 °C. Then, 50 μL 1.25 mg/mL BIO-
PHEN CS-11(32) [Suc-IIe-Gly-(γPip)Gly-Arg-pNA, HCl] chromogenic 
substrate (Hyphen BioMed, Neuville sur Oise, France) was added 
and the release of pNA by uninhibited FXa was recorded at 405 nm 
for 60 s. The same assay components were used for the determination 
of hc activity, with the following exceptions: in this case polybrene 
was replaced by 1 U/mL heparin in the dilution buffer, the dilution of 
plasma samples was 50-fold and the incubation with FXa was short-
ened to 60 s. The ΔA/min values were converted to percentage of 
mean normal anti-FXa activity. Calibration curve was set-up by meas-
urement on dilutions of HemosIL™ Calibration plasma (Instrumen-
tation Laboratory, Milano, Italy) recalibrated on the mean p-anti-FXa 
activity and hc-anti-FXa activity in the reference population as 100%. 
The hc-anti-FXa activity assigned for this calibration plasma by the 
manufacturer only slightly (+2%) deviated from the values calcu-
lated on the basis of the means obtained in the reference population. 
AT antigen was measured by immunonephelometry (Siemens, BN 
ProSpec® System AT-III). The antibody used in the assay is a poly-
clonal one raised against purified AT. It is very likely directed against 
different epitopes, which are not given by the manufacturer. Anti-FXa 
activity and AT antigen determinations for patients with thrombosis 
were carried out at least 3 months from the thrombotic events.
Method evaluation
Commercially available plasmas, HemosIL™ Normal Control and Low 
Abnormal Control, (Instrumentation Laboratory) were used for the 
evaluation of precision performance of anti-FXa assays. The evalua-
tion was carried out according to the EP15-A2 guideline of Clinical and 
Laboratory Standards Institute (CLSI; Wayne, PA, USA) using single run 
per day with duplicate determinations for 20 days. For the estimation 
of constant error due to hemoglobin, bilirubin and triglyceride interfer-
ence plasma samples were supplemented with red blood cell lysate, 
Intralipid (Baxter, Deerfield Park, IL, USA) and concentrated bilirubin 
solution in dimethylsulfoxide (Sigma-Aldrich, St. Louis, MO, USA), 
respectively (CLSI document C56-A). To determine what portion of 
p-anti-FXa activity was due to FXa inhibitor plasma proteins other than 
AT, the anti-FXa activities of AT deficient plasma (Enzyme Research 
Laboratories, Swansea, UK), 2.0 mg/mL purified α1-antitrypsin and α2-
macroglobulin (both from Sigma-Aldrich) were also measured.
Reference intervals were established as described in the CLSI 
EP28-A3c guideline [21]. The need for partitioning of reference val-
ues according to gender was investigated by the z statistic and by the 
ratio of SD values.
Statistical analysis
The distribution of the results was analyzed by the Kolmogorov-
Smirnov test with Lilliefors correction and by the Shapiro-Wilk tests. 
Student’s t-test was used to analyze differences in variables between 
the subgroups of individuals. Calculations and construction of 
graphs were performed by GraphPad Prism 5.0a software (La Jolla, 
CA, USA).
Results
Development of chromogenic progressive 
anti-FXa assay
For the measurement of p-anti-FXa activity the hc-anti-
FXa assay had to be modified at several points. Polybrene 
was included in the assay buffer to neutralize heparin 
in the plasma of patients treated with heparin or to 
eliminate the effect of heparin contamination. As in the 
absence of heparin the inhibition of FXa by AT progresses 
only slowly, the incubation time and the plasma volume 
had to be increased to obtain a well-measurable inhibi-
tion. Figure 1A demonstrates the dependence of anti-FXa 
activity on plasma dilution and the time of FXa incuba-
tion with diluted plasmas. For the final routinely used 
assay, 5-fold diluted plasma and 5  min incubation time 
were selected, i.e., the plasma volume was increased 
10-fold and the incubation time was prolonged 5-fold as 
compared to the hc-anti-FXa assay. The calibration curve 
for the assay using HemosIL™ Calibration plasma is 
shown on Figure 1B.
The evaluation of progressive anti-FXa assay
The assay has an excellent reproducibility, within labora-
tory imprecision was below 4% (Table 1). Hemoglobin up 
to 500 mg/L, bilirubin up to 200 μmol/L and triglyceride 
up to 10 mmol/L did not interfere with the assay (Figure 2). 
As in addition to AT, there are other proteins with anti-
FXa activity in the plasma, we estimated the contribution 
of such proteins to the measured p-anti-FXa activity and 
hc-anti-FXa activity. First, the anti-FXa activities of com-
mercially available pooled plasma immunodepleted from 
AT was measured. The p-anti-FXa activity of this plasma 
was 20.4% of mean normal p-anti-FXa activity measured 
on the reference population. The hc-anti-FXa activity of 
the immunodepleted plasma did not differ significantly 
from zero. As α1-antitrypsin and α2-macroglobulin also 
possess some heparin-independent anti-FXa activity 
[22, 23], they were suspected to be the primary sources 
of non-AT p-anti-FXa activity and the inhibitory effect of 
purified α1-antitrypsin and α2-macroglobulin in the range 
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of their normal plasma concentration was determined. 
The p-anti-FXa activity of 2.0 mg/mL α1-antitrypsin cor-
responded to 9.5% of normal plasma p-anti-FXa activity, 
while α2-macroglobulin in the same concentration exhib-
ited only 4.0% inhibitory activity. These findings indicate 
that AT is responsible for approximately 80% of p-anti-
FXa activity present in the plasma.
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Figure 2 The influence of interfering substances (hemoglobin, 
triglyceride and bilirubin) on the progressive anti-FXa assay.
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Figure 1 Characteristics of chromogenic progressive (p) anti-FXa 
activity assay.
(A) The dependence of anti-FXa activity on the dilution of pooled 
normal plasma and on the time of incubation of FXa with diluted 
plasmas. The measurements were carried out in the presence of 
the heparin antagonist, polybrene. □, Fifty-fold plasma dilution; ■, 
10-fold plasma dilution; ○, 5-fold plasma dilution. The latter plasma 
dilution and 300 s incubation time were selected for the routine 
assay. (B) Calibration curve for the assay. mAbs, milliabsorbance at 
405 nm.
Table 1 The precision of progressive anti-FXa assay.
  Normal control plasma   Pathologic control plasma
Mean ± sr   102.3 ± 2.2%   41.9 ± 0.8%
  CV: 2.15%   CV: 1.89%
Mean ± sl   102.3 ± 3.3%   41.9 ± 1.6%
  CV: 3.20%   CV: 3.75%
CV, coefficient of variation; sl, within-laboratory precision; sr, repeat-
ability (within-run precision).
Reference intervals for progressive and 
heparin cofactor anti-FXa activities
The distribution of both hc-anti-FXa and p-anti-FXa activi-
ties was normal as verified by two statistical methods 
(Figure 3). No outlier was found among the results. Cal-
culation of the reference interval for hc-anti-FXa activity 
by parametric and non-parametric method gave prac-
tically identical results, 82%–118% and 81%–117% of 
normal average, respectively. For p-anti-FXa activity the 
calculated reference interval was 82%–118% (parametric 
method) and 84%–117% (non-parametric method).
Comparison of heparin cofactor anti-FXa 
activity, progressive anti-FXa activity and 
antithrombin antigen concentration in 
patients with antithrombin deficiency
Table 2 demonstrates the hc-anti-FXa activity, p-anti-FXa 
activity and the AT antigen concentration of all individual 
AT deficient patients. The causative mutations leading to 
AT deficiency are also shown in the table. The great major-
ity of the patients had type II-HBS deficiency, and among 
them p.Leu99Phe (AT Budapest 3 [24]) was the dominant 
mutation. Among symptomatic AT-deficient patients 
diagnosed in our laboratory between 2010 and 2013, 81% 
proved to be type II-HBS deficient and 88% of whom pos-
sessed the p.Leu99Phe mutation [20]. In addition to the 
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18 homozygotes and 43 heterozygotes for the p.Leu99Phe 
mutation, three heterozygous patients with p.Pro41Leu 
(AT Basel [25, 26]) mutation and five heterozygotes with 
p.Arg47His (AT Padua I [27]) mutation were also included 
in the group of patients with type II-HBS AT deficiency.
As expected, in type II-HBS AT deficient patients with 
homozygous p.Leu99Phe mutation the hc-anti-FXa activi-
ties were very low (mean: 13.1%, median 12%, total range: 
8%–26%). In contrast, the p-anti-FXa activities were much 
higher overlapping with the reference interval (mean: 
78.4%, median: 77%, total range 64%–106%) (Table 2). The 
AT antigen concentrations (mean: 76.4%, median: 79%, total 
range 51–98) corresponded to the p-anti-FXa activities. The 
somewhat lower than normal p-anti-FXa activities and AT 
40
30
20
10
0
hc-anti-FXa activity, %
78.9
82.8
86.6
90.4
94.3
98.1
101.9
105.8
109.6
113.4
117.3
121.1
p-anti-FXa activity, %
79 83 87 91 95 99 103 107 111 115 119 123
Fr
e
qu
en
cy
40
30
20
10
0
Fr
e
qu
en
cy
Figure 3 The distribution of heparin cofactor (hc) and progressive 
(p) anti-FXa activity in a healthy reference population.
The normal distribution of the results was proven for both assays 
by the Kolmogorov-Smirnov test with Lilliefors correction (hc-anti-
FXa d: 0.043, p: 0.2; p-anti-FXa statistic: 0.058, p: 0.2) and by the 
Shapiro-Wilk test (hc-anti-FXa assay d: 0.994, p: 0.634; p-anti-FXa 
assay: statistic: d: 0.989, p: 0.154).
antigen concentrations in this group suggest that the muta-
tion, in addition to abrogating heparin binding, to a minor 
extent, also influences the synthesis/secretion of the mol-
ecule. In p.Leu99Phe heterozygotes the decrease of hc-anti-
FXa activity corresponded to the heterozygous state (mean: 
50.8%, median: 51%, total range: 34%–65%) (Table 2), 
while the p-anti-FXa activity (mean: 90.5%, median 90%, 
total range: 66%–111%) only marginally decreased and 
there was no overlap between the ranges of the two anti-
FXa activities. In this group both the mean and median AT 
antigen concentration were 99% (total range: 78%–118%). 
The number of type II-HBS AT deficient patients with 
mutations other than p.Leu99Phe was too small to allow 
detailed evaluation. However, even in the combined group 
of patients heterozygous for p.Pro41Leu or p.Arg47His 
mutation the hc-anti-FXa activities were below the lower 
limit of reference interval, while the p-anti-FXa activities 
were within the reference interval and were comparable to 
the AT antigen values. In the case of type I heterozygotes 
plus and in the single type II-PE heterozygote both anti-FXa 
activities were below the reference interval, just like the AT 
antigen values in type I deficient patients (Table 2).
p-anti-FXa/hc-anti FXa ratio in the diagnosis 
of type II-HBS AT deficiency
The above results suggested that comparing p-anti-FXa 
and hc-anti-FXa activities could be a useful tool in the 
diagnosis of type II-HBS AT deficiency. The calculated 
ratios p/hc ratios for each AT deficient group and their 
healthy relatives are shown on Figure 4. The ratios for 
type II-HBS heterozygotes are well above the upper limit 
of the reference interval for p/hc ratios (0.87–1.14), and are 
clearly separated from the group of wild type relatives. In 
the case of homozygous type II-HBS AT deficient patients 
the ratios are very high, much higher than those of het-
erozygotes. In the case of type I AT deficient patients the 
p-anti-FXa activity is somewhat higher than the hc-anti-
FXa activity (Table 2), which is reflected in ratios being 
above the reference interval (Figure 4). This is very likely 
due to the approximately 20% contribution of FXa inhibi-
tors other than AT to the plasma p-anti-FXa activity (see 
above); evidently, the concentration of these inhibitors is 
not decreased in type I deficiency.
Discussion
Large scale prospective epidemiological studies involv-
ing AT, protein C or protein S deficient individuals and 
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Table 2 Heparin cofactor and progressive anti-FXa activities and antithrombin antigen concentrations in patients with antithrombin 
deficiency.
AT deficiency   Gender   hc-anti-FXa 
activity, %
  p-anti-FXa 
activity, %
  AT antigen, 
%
  Mutation
Type II-HBS homozygotes   M   8   64   51  p.Leu99Phe
n = 18   F   8   77   76  p.Leu99Phe
  F   12   77   80  p.Leu99Phe
  F   16   83   79  p.Leu99Phe
  F   15   88   79  p.Leu99Phe
  F   9   83   74  p.Leu99Phe
  M   20   79   70  p.Leu99Phe
  M   14   106   85  p.Leu99Phe
  F   12   75   77  p.Leu99Phe
  F   10   72   83  p.Leu99Phe
  F   10   66   52  p.Leu99Phe
  M   14   81   90  p.Leu99Phe
  M   10   72   82  p.Leu99Phe
  F   10   66   63  p.Leu99Phe
  F   20   97   84  p.Leu99Phe
  M   8   74   82  p.Leu99Phe
  F   26   84   71  p.Leu99Phe
  F   13   68   98  p.Leu99Phe
Type II-HBS heterozygotes   F   46   94   101  p.Leu99Phe
n = 51   F   47   97   99  p.Leu99Phe
  M   58   96   96  p.Leu99Phe
  M   65   101   109  p.Leu99Phe
  F   52   90   90  p.Leu99Phe
  M   54   83   nd  p.Leu99Phe
  M   51   88   97  p.Leu99Phe
  M   41   84   79  p.Leu99Phe
  M   53   93   106  p.Leu99Phe
  F   52   94   88  p.Leu99Phe
  F   50   97   90  p.Leu99Phe
  M   55   102   nd  p.Leu99Phe
  M   54   94   nd  p.Leu99Phe
  M   58   111   100  p.Leu99Phe
  F   53   98   96  p.Leu99Phe
  M   59   102   nd  p.Leu99Phe
  F   48   83   108  p.Leu99Phe
  M   56   87   106  p.Leu99Phe
  M   56   96   118  p.Leu99Phe
  F   51   85   114  p.Leu99Phe
  M   49   98   nd  p.Leu99Phe
  F   57   109   102  p.Leu99Phe
  F   59   107   nd  p.Leu99Phe
  F   63   106   nd  p.Leu99Phe
  F   46   77   92  p.Leu99Phe
  M   52   91   103  p.Leu99Phe
  F   52   89   100  p.Leu99Phe
  M   47   85   96  p.Leu99Phe
  F   51   84   92  p.Leu99Phe
  M   40   80   107  p.Leu99Phe
  F   48   85   106  p.Leu99Phe
  M   34   75   85  p.Leu99Phe
  M   53   86   98  p.Leu99Phe
  F   47   85   102  p.Leu99Phe
  F   49   92   104  p.Leu99Phe
  M   47   84   96  p.Leu99Phe
  M   52   90   102  p.Leu99Phe
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AT deficiency   Gender   hc-anti-FXa 
activity, %
  p-anti-FXa 
activity, %
  AT antigen, 
%
  Mutation
  F   54   101   108  p.Leu99Phe
  M   50   82   113  p.Leu99Phe
  M   51   86   95  p.Leu99Phe
  F   39   66   78  p.Leu99Phe
  M   48   83   91  p.Leu99Phe
  F   36   74   96  p.Leu99Phe
  M   73   117   108  p.Pro41Leu
  F   54   110   132  p.Arg47His
  F   48   99   120  p.Arg47His
  F   66   126   137  p.Arg47His
  M   66   123   130  p.Arg47His
  F   65   108   124  p.Pro41Leu
  F   74   116   130  p.Pro41Leu
  F   54   86   nd  p.Arg47His
    4      
Type II-PE heterozygote   M   76   78   88  p. Pro407Thr
Type I heterozygotes   F   56   75   58  Arg132X
n = 8   F   53   74   54  Arg132X
  F   43   56   56  Arg132X
  M   49   64   63  c.807delT 
p.Leu238ArgfsX13
  F   46   69   72  p.Glu237Lys
  M   46   61   61  IVS5-14G > A
  F   56   76   64  dup c. 315–319
  M   48   71   52  dup c. 315–319
With the exception of the novel dup c. 315–319 defect, all mutations are included in the antithrombin mutation database [38]. It is to 
be noted that p.Glu237L mutation (AT Truro [39]) in the database is considered as type II mutation and increased heparin affinity of the 
recombinant mutant was demonstrated [40, 41]. However, in the original publication the AT antigen and activity levels were 66% and 68%, 
respectively. As in our study the AT antigen level was also decreased, this deficiency was treated as type I. AT, antithrombin; F, female; FXa, 
activated factor X; HBS, heparin binding-site defect; hc-anti FXa activity, heparin cofactor anti-FXa activity; M, male; p-anti FXa activity, 
progressive anti-FXa activity; PE, mutation with pleitropic effect.
individuals with Factor V Leiden mutation indicated that 
the risk of first VTE conferred by hereditary AT deficiency 
is the highest among inherited thrombophilias [28]. The 
relative risk of VTE in patients with AT deficiency was 
estimated to be approximately 25–50-fold [29–32]. AT defi-
ciency also represents an increased risk of pulmonary 
embolism and recurrence of VTE [16, 33, 34]. The clinical 
phenotype of type II-HBS AT deficiency is different from 
that of type I, and other type II AT deficiencies [19, 35, 36]. 
Heterozygous type II HBS deficiency represents milder 
type of thrombophilia the severity of which is comparable 
to that of heterozygous FV Leiden mutation. In this case 
homozygosity is not lethal, but severe thrombosis usually 
occurs at an early age (frequently in childhood). A distinc-
tion between type II-HBS and other type of AT deficien-
cies as well as between the homozygous and heterozygous 
forms is of considerable clinical importance. It might 
influence the prediction of the risk of recurrent throm-
botic events and might also influence the clinical decision 
concerning the duration of anticoagulant therapy.
The first line test in the diagnosis of AT deficiency is a 
functional chromogenic hc assay, according to our former 
results [20] preferably an anti-FXa assay. In the previ-
ous study we showed that in 95% of heterozygotes with 
genetically proven type II-HBS AT deficiency, anti-FIIa 
activities were in the reference interval, i.e., this test failed 
to recognize the defect. At the same time the hc-anti-FXa 
activities were diagnostic in all cases. In homozygotes for 
type II-HBS AT deficiency the anti-FIIa activity was much 
higher (48%–80%) than the anti-FXa activity (9%–25%). 
The addition of AT antigen measurement allows differ-
entiation between type I and type II AT deficiencies, but 
does not identify the type II-HBS subtype. The diagnosis 
of this deficiency by functional tests requires the com-
parison of p-anti-FXa and hc-anti-FXa AT activities, in 
which tests AT activity is measured in the absence and 
presence of heparin, respectively. The progressive assay is 
very much under-utilized in the diagnosis and classifica-
tion of AT deficiencies [19]. The old clotting assays of AT 
activity in the absence of heparin were too cumbersome 
(Table2  Continued)
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and difficult to interpret [37, 38]. A chromogenic anti-FXa 
assay in the absence of heparin has been advocated and 
used in the diagnosis of a patient with type II-HBS AT defi-
ciency [19]. Unfortunately, this assay has not been evalu-
ated. In the application sheet of some of the commercially 
available hc-anti-FXa assays it is mentioned that the test 
can be carried out in the absence of heparin, but no spe-
cific details are given. A former application sheet from 
HYPHEN BioMed (West Chester, OH, USA) recommended 
1-h incubation of FXa with the patient plasma (http://
www.aniara.com/pdf/SS-ANIARA-Prog-ATIII.pdf), which 
hardly allows an automated kinetic procedure. Here we 
describe an anti-FXa assay, which, with a simple change 
of buffer, can be used for both p-anti-FXa and hc-anti-
FXa activity determinations. The 5-min incubation time 
allows automation of the assay; we have adapted it to two 
routine coagulometers. The inclusion of polybrene in the 
assay buffer of p-anti-FXa measurement made it possi-
ble to perform the assay on plasma from heparin-treated 
patients and unnoticed heparin contamination would not 
interfere with the assay. The method is of excellent repro-
ducibility and hemoglobin, bilirubin and triglyceride up 
to high concentrations do not interfere with the assay.
To our surprise no reference interval determined 
according to CLSI guideline (C28-A3) was found in the 
literature for hc-anti-FXa activity. A number of different 
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Figure 4 The ratio of progressive (p) and heparin cofactor (hc) 
anti-FXa activity in different types of antithrombin deficiency and in 
non-deficient wild type relatives (controls).
HBS, heparin binding-site deficiency; +/+, homozygote; +/-, het-
erozygote; -/-, wild type controls. The two broken horizontal lines 
represent the lower (0.87) and upper (1.14) limits of the reference 
interval for p/hc-anti-FXa ratios. The reference interval was calcu-
lated from the results of reference sample group by non-parametric 
method.
‘normal’ ranges, varying within a relatively narrow inter-
val, have been reported and are available in manufactur-
ers’ application sheets. Based on these results 80% of the 
average normal (0.8 IU/mL) is generally accepted as the 
lower limit of reference interval. Following the C28-A3 
guideline we found a value of 81% (0.81 U/mL), which 
confirmed the generally used lower limit. The same stands 
for the upper limit, but to our knowledge, no clinical rel-
evance has been associated with AT activities exceeding 
the upper limit of the reference interval. For the first time 
we also determined the reference interval for the p-anti-
FXa AT assay. Similar to the case of hc-anti-FXa assay, a 
narrow reference interval (84%–117%) was established for 
this assay, as well.
From clinical point of view it is desirable to distinguish 
among subtypes of AT deficiencies with different risk of 
thromboembolic complications. The usefulness of parallel 
p-anti-FXa and hc-anti-FXa determination in the classifi-
cation of AT deficiencies is demonstrated in Table 2 and 
Figure 4. The range of p/hc ratios for II-HBS heterozygous 
patients (1.54–2.21) was well above the upper limit of the 
reference interval (1.14) and clearly separated from that 
of wild type relatives (range: 0.92–1.09). The p/hc ratios 
for patients with type I AT deficiency were also above 
the reference interval but below the range of type II-HBS 
heterozygotes. As the classification of type I deficiency is 
based on concomitantly low AT activity and antigen level, 
even the overlap of the ranges of type I and type II-HBS het-
erozygotes would not cause any diagnostic problems. Most 
importantly, the p/hc ratios also allowed a clear distinc-
tion between type II-HBS heterozygotes and homozygotes 
(range: 3.23–9.63); such distinction is of considerable clini-
cal importance. In summary, the chromogenic anti-FXa 
assay described above allows the parallel determination 
of p-anti-FXa and hc-anti-FXa activities and, even in the 
absence of molecular genetic investigation, provides a reli-
able diagnosis of type II-HBS deficiency and distinguishes 
between homozygotes and heterozygotes.
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